Forty-two defibrillating lead systems for the automatic implantable defibrillator were implanted and tested in 41 patients. Two basic lead configurations were used: 1) spring-patch, consisting of a transvenous superior vena cava spring electrode as the anode and an apical or left lateral ventricular patch electrode (either small [13.9 cm 2 ] or large [27.9 cm 2 ]) as the cathode; and 2) patch• patch, consisting of an anterior right ventricular patch as the anode and a posterior left ventricular patch as the cathode. Of the 42 lead systems, 10 were spring• patch and 32 were patch-patch combinations. The de• fibrillation threshold for the patch-patch combinations (9.8 ± 6.5 J, mean ± standard deviation) was signifi• cantly (p < 0.01) lower than that for the spring-patch combinations (19
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The automatic implantable defibrillator (AID-B, Intec Sys• tems) is a device capable of automatically identifying and correcting ventricular tachycardia and fibrillation (1) (2) (3) and has been shown to significantly increase survival in patients at high risk for recurrent cardiac arrest (4) . The current device is a result of an evolutionary development process begun by investigators over a decade ago (5) (6) (7) (8) .
The defibrillating lead system of the automatic implant• able defibrillator in the majority of human implants has consisted of a trans venous spring electrode (a titanium coil with a surface area of 6.5 cm 2 ; personal communication, S. M. Bach, Jr., MD, Intec Systems) serving as the anode, and an apical or left lateral ventricular patch electrode (a titanium mesh flat electrode with a surface area of either 13.9 or 27.9 cm 2 ) serving as the cathode (spring-patch configuration) .
combinations with at least one large patch. Total surface area of defibrillating leads was strongly negatively cor• related with the defibrillation threshold (p < 0.005).
Analysis of the relation of clinical variables to defi• brillation threshold revealed that only amiodarone ther• apy was independently associated with a significantly (p < 0.05) higher defibrillation threshold. Thus, surface area of the defibrillating leads is a critical determinant of the defibrillation threshold for the implanted defi• brillator. Patch-patch lead systems with at least one large patch may provide an increased safety margin for de• fibrillation. Conversely, amiodarone therapy is associ• ated with higher defibrillation thresholds and may de• crease the margin of safety. (J Am Coli Cardiol 1985; 6:1315-21) It is also possible to use two patch electrodes for defi• brillation (patch-patch configuration). This configuration is obtained by placing one patch posteriorly or posterolaterally on the left ventricle, with the second patch positioned an• teriorly over the right ventricle. Two small patches, two large patches or one of each size are possible options for the patch-patch configuration.
It has been reported by Winkle et al. (9) that when reliable defibrillation is not obtainable with 25 to 30 J (the output of the currently used automatic implantable defibrillator gen• erator) using the spring-patch configuration, the patch-patch configuration may result in lower defibrillation thresholds. This report summarizes our experience with various defi• brillating lead configurations in the first 41 patients undergo• ing lead implantation at our institution.
Methods
Study patients. Forty-one consecutive patients who had the lead system of the automatic implantable defibrillator implanted were studied. One patient had two lead system implants because infection necessitated removal of the first system. The defibrillating lead configuration and patient characteristics are shown in Table 1 . Thirty-two of the 41 patients were male and 9 were female, ranging in age from 13 to 81 years (mean 57.4).
Thirty-two of the patients had experienced an episode of cardiac arrest and nine had symptomatic recurrent sustained hypotensive ventricular tachycardia. Thirty-six patients had coronary artery disease, three patients had nonischemic congestive cardiomyopathy, one patient had hypertrophic JACC Vol. 6. No.6 Defibrillating Lead Configuration
Ps-Ps was placed by means of a left anterior thoracotomy in 12 patients and a median sternotomy in 30 patients. Of the latter 30 patients, 29 underwent a surgical procedure in addition to lead system placement. Coronary artery bypass grafting was performed in 15 patients, bypass grafting in conjunction with left ventriculotomy (with subendocardial resection or cryoablation, or both) in 12 patients (I of whom also underwent repair of a congenital atrial septal defect) and left ventriculotomy alone (with subendocardial resection or cryoablation, or both) in 2 patients. When other cardiac operations were performed, the automatic implantable de• fibrillator leads were installed and tested after these pro• cedures had been completed. Electrode positioning. In all instances, the placement of the electrodes was designed to include the largest mass of myocardium possible between them. The initial electrode configuration was determined by the operating surgeon on the basis of his intraoperative assessment. During the first 10 implants, a spring-patch configuration was utilized and not altered unless unacceptably high defibrillation thresholds were obtained. During subsequent implants (partially due to experience with difficulty in spring electrode placement and migration of several spring electrodes out of position), a two patch configuration was elected, again with the size of the implanted patches being chosen by the operating surgeon. A number of factors influenced the decision re• garding choosing the patch size, including the location of any aortocoronary vein grafts, internal mammary artery grafts or ventriculotomy and overall cardiac size.
When utilized, the spring electrode (the anode of the shocking lead system) was introduced through a l4F in• troducer placed by means of a percutaneous puncture of one of the subclavian veins and advanced under fluoroscopic guidance to the mid right atrium. In three cases, the spring electrode was introduced through the innominate vein when technical factors precluded passage from either subclavian approach. The patch electrode (cathode of the shocking lead system) for the spring-patch configuration was then placed over the apical or lateral left ventricle and secured by su• turing its edges to the ventricular epicardium. When two patches were utilized (patch-patch configuration), one was sutured to the anterior right ventricular surface (and served as the anode) and the other was sutured to the posterior or posterolateral left ventricular epicardium (and served as the cathode). Two epicardial screw-in electrodes (model K-54, Intec Systems) were employed to record e1ectrograms for rate counting and synchronization of shocks. In one patient, an endocardial rate counting lead was used because of in• adequate e1ectrographic recordings from the epicardial surface.
Defibrillation threshold testing. Intraoperative defi• brillation threshold testing was performed after the lead system was installed utilizing an external cardioverter de• fibrillator (Intec Systems) that delivers a truncated expo• nential shock waveform (identical to the waveform of the TROUP ET AL.
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DETERMINANTS OF DEFIBRILLATION THRESHOLD automatic implantable defibrillator pulse generator), with adjustable delivered energies from I to 40 J (in increments of I J at energy levels between I and 5 J and increments of 5 J at energy levels between 5 and 40 1). Ventricular fibrillation was induced by brief epicardial application of 60 Hz. 7.2 V (root mean square) alternating current. The shocks were delivered after 5 to 10 seconds of ventricular fibrillation. Ventricular fibrillation was defined as a ven• tricular tachyarrhythmia during which distinct QRS com• plexes could not be discerned in the surface electrocardio• graphic leads (I, aVF and V 6 ) .
The initial energy level tested was 20 J. If successful, decrements of 5 J were tried until the 5 J level was reached or defibrillation was unsuccessful. If 5 J was successful, a I J shock was then tested. All unsuccessful attempts were followed immediately by a 40 J "rescue" shock, so that only one energy level was tested for each episode of ven• tricular fibrillation. Defibrillation trials were separated from one another by intervals of I minute. If the initial 20 J shock was unsuccessful, increments of 5 J were tested until de• fibrillation was achieved. The first unsuccessful shock and the lowest successful energy level were then repeated once. The defibrillating threshold was defined as the lowest energy that terminated ventricular fibrillation. Statistical analysis. Unpaired t tests and the one-way analysis of variance (10) were used to evaluate the effects of several factors on the defibrillation threshold. These fac• tors were gender, diagnosis, presenting arrhythmia, con• comitant cardiovascular surgery and treatment with amio• darone, digoxin or one or more type I antiarrhythmic drugs (as defined by Vaughan Williams [ll]). Pearson's corre• lation was used to evaluate the effects of age, surface area of defibrillating leads (total exposed titanium surface of the anode plus the cathode) and left ventricular ejection fraction (12). Multiple linear regression was then used to extract those variables providing independent information regarding the defibrillation threshold. All data are expressed as mean values ± I SD.
Results
Relation of lead configuration to defibrillation thresh• old. Of the 42 lead systems, 10 were spring-patch (Fig. 1 ) and 32 were patch-patch (Fig. 2) combinations. The mean defibrillation threshold for all of the patch-patch combina• tions (9.8 ± 6.5 J) was significantly (p < 0.01) lower than that for the spring-patch configuration (19.1 ± 10.3 1). Subgroup analysis based on lead configuration, patch size and surface area of the defibrillating leads is shown in Figure  3 . The total surface area of the shocking leads was strongly negatively correlated with the defibrillation threshold (p < 0.005); the larger exposed lead areas yielded the lowest defibrillation thresholds. The lowest thresholds were ob- tained with patch-patch configurations having at least one large patch.
Influence of clinical variables on defibrillation thresh• old (Table 2) . Amiodarone therapy was associated with a significantly (p < 0.05) higher defibrillation threshold. Al• though patients with cardiomyopathy and those taking dig- oxin had a higher mean defibrillation threshold, this differ• ence did not reach statistical significance. Similarly, age, presenting arrhythmic event, use of a type I antiarrhythmic drug and whether additional cardiac surgery was performed had no statistically significant effect on defibrillation thresh• old. The lower mean defibrillation threshold for the group having aneurysmectomy alone was not significantly differ• ent from the mean defibrillation threshold for patients having no additional cardiac surgery. There was also no relation between defibrillation threshold and left ventricular ejection fraction (r = 0.022, P = NS). Age was negatively cor• related with defibrillation threshold (r = -0.364, P < 0.01).
Multivariate analysis. When the variables were com• bined in a multivariate analysis, the surface area of the defibrillating leads was most strongly associated with de• fibrillation threshold (p < 0.01). Amiodarone therapy also continued to contribute a significant (p < 0.05) effect on the defibrillation threshold. Patient age did not contribute any significant additional independent information in this analysis.
Discussion
Lead configuration and defibrillation threshold. The implanted defibrillator was initially conceived as a totally transvenous device utilizing a catheter electrode system (13). Subsequently, it was shown in dogs that the most consistent and lowest energy requirements for defibrillation were achieved with patch electrodes placed on the base and apex of the heart (6, 14) . A superior vena cava spring electrode with an apical patch electrode was found to be almost as effective and functioned well in a chronic dog model (IS), and was then adopted for the initial human implants (I) .
Our data indicate that the surface area of the defibrillating leads is one critical determinant of the energy required to achieve defibrillation. Defibrillation relates to the delivery of a current density adequate to depolarize a critical mass of myocardium (16) . In studies of transthoracic defibrilla• tion, it has been shown in dogs that larger electrode paddles improved the success rate of ventricular defibrillation (17) , possibly related to a lower transthoracic impedance with larger electrode paddles (18, 19) . Electrode surface area may become excessive, however, resulting in more extracardiac currentftow, with inadequate current density delivered to the heart for defibrillation (20) . An analogous situation may well exist with implanted defibrillating electrode systems. Patch systems that are excessively large may lead to "shunt• ing" of current between the edges of the electrodes instead of through the intervening myocardium. Optimal electrode size for the implanted shocking leads has not been defined and, in fact, will probably need to be individualized. As a practical matter, because the automatic implantable defi• brillator has a finite delivered energy in the range of 25 to 
35 J, factors that reduce the threshold for defibrillation will increase the margin of safety, Our data strongly suggest that one means of reducing the defibrillation energy requirement is the implantation of a two patch electrode system and that, preferably, the system should include at least one large patch. Effect of antiarrhythmic agents on defibrillation threshold. Amiodarone therapy was associated with a sig• nificantly higher defibriIlation threshold independent of the surface area of the defibrillating leads or any other variable analyzed, Therefore, if a patient with an implanted defi• brillator is started on amiodarone therapy, repeat testing is mandatory to ensure that the device is still capable of achiev• ing defibrillation. Conversely, if a patient already taking amiodarone has a relatively high defibrillation threshold, discontinuing the drug may lower the threshold to a more acceptable level. Amiodarone-induced refractoriness to car• dioversion (using the implanted defibrillator lead system) has been reported by Fogoros (21) in a patient in whom a 40 J shock delivered through the implanted leads was un• successful in terminating ventricular fibrillation while the patient was receiving amiodarone therapy. After discontin• uation of amiodarone for 3 months, defibrillation was ac• complished with 10 J.
The role of other antiarrhythmic agents in this context is not well defined. In the current study, no significant re• lation was found between either digoxin therapy or type I antiarrhythmic drug therapy and defibrillation threshold (al- 11.4 CM = cardiomyopathy; NS = not significant; other abbreviations as in Table I. though it should be noted that the statistical analysis did not address individual type I antiarrhythmic agents due to the multiplicity of single agents employed). This is in agreement with data from animal experiments (22) suggesting that there is no acute change in defibrillation threshold with digoxin or procainamide (administered by intravenous bolus) using the automatic implantable defibrillator lead system. How• ever, several type I antiarrhythmic drugs (lidocaine, phe• nytoin and quinidine) have been reported (23, 24) to raise transthoracic ventricular defibrillation thresholds in dogs. In contrast, bretylium and clofilium have been shown to decrease the canine transthoracic ventricular defibrillation threshold (25) , an effect with potential benefit in patients with implanted defibrillators. The effects of antiarrhythmic and other drugs on defibrillation thresholds with implanted lead systems is ih need of further investigation.
Limitations of the study. The clinical determination of the defibrillation threshold as a single quantity of energy, implying a sharp distinction between effective and ineffec• tive energy levels, is probably a misleading concept. It has been shown in dogs that there is a range of energies that are more or less successful in producing defibrillation (26) . During our initial implantation experience, it was not clear how well defibrillation threshold testing would be tolerated by patients. Therefore, we elected to minimize the number of fibrillation-defibrillation trials. We have, however, noted no untoward effects from the defibrillation trials. Similarly, it would have been informative to test every lead configu• ration in every patient (which would have allowed the patient to serve as his or her own control). Once a satisfactory lead configuration was found, however, we elected not to con• duct trials of other lead configurations to minimize the po• tential for patient morbidity. Additionally, it should be noted that random selection of energies for the defibrillation trials might have given additional information regarding the effect of time and previous shocks on the efficacy of subsequent shocks since in our present protocol, lower energy shocks Were delivered only after successful higher energy shocks.
The data reported are specific to the lead systems and the truncated exponential waveform utilized by the Intec device. Extrapolation of these results to other defibrillation waveforms is not possible.
Conclusions. There is a significant relation between de• fibrillating lead configuration and defibrillation threshoid for the automatic implantable defibrillator. Specifically, it ap• pears that lead surface area is a critical determinant. Patch• patch lead systems with at least one large patch were as• sociated with the lowest defibrillation thresholds and may provide a larger margin of safety for defibrillation. Addi• tionally, amiodarone therapy was associated with signifi• cantly higher defibrillation thresholds. Therefore, defibril• lation testing should be repeated if amiodarone therapy is initiated after defibrillator implantation to ensure continued efficacy. Because the time course of amiodarone effect on JACC Vol. 6, No.6 December 1985'\315-21 defibrillation threshold is unknown, the. timing of repeat testing is empiric and we select an arbitrary time 4 to 6 weeks after initiation ot the drug. Recommendat~ons re• garding other antiarrhythmic agents await further delineation of their role in modulating the defibrillation threshold.
